Dosimetry of beta sources for cardiovascular brachytherapy  by Bulski, Wojciech et al.
Dosimetry of beta sources for cardiovascular brachytherapy
Wojciech Bulski1, Stanisław Pszona2, Maria Kawczyńska1
1Centre of Oncology, Roentgena 5 St., 02-781 Warszawa, 2Institute of Nuclear Studies, 05-400 Otwock-Świerk  
Rep Pract Oncol Radiother 2004;9:33-6, original paper
Received January 28th, 2004; received in a revised form April 14th, 2004; accepted April 15th, 2004
Proceedings of the Conference „Current Archievements in Oncology” Poznań, 6-8 November 2003
Praca prezentowana na konferencji „Współczesne Osiągnięcia w Onkologii” Poznań, 6-8 listopada 2003
Streszczenie
Wstęp: W okresie ostatnich dziesięciu lat zastosowanie promieniowania jonizującego w zapobieganiu restenozie było powszechnie 
stosowane.   Celem niniejszego doniesienia była weryfikacja procedur używanych w wyznaczaniu aktywności i jednorodności jej rozkładu 
dla liniowych  źródeł P-32 stosowanych w brachyterapii choroby wieńcowej.
Materiał i metody: Pomiary aktywności i jednorodności jej rozkładu przeprowadzono dla źródeł promieniowania beta stosowanych w 
aparacie Galileo firmy Guidant. Pomiary aktywności prowadzone były przy pomocy studzienkowej komory jonizacyjnej. 
Wyniki i dyskusja: Dla wszystkich badanych źródeł aktywność wyznaczana za pomocą studzienkowej komory jonizacyjnej zgadzała się 
z dokładnością  1.5% z wielkością aktywności podawaną przez producenta.  Wyniki pomiarów świadczą, że rozkład aktywności wzdłuż 
źródła jest jednorodny w zakresie ±5%.  Spadek mocy dawki w funkcji odległości od osi źródła wyznaczony za pomocą filmów radiochro-
mowych był zgodny z obliczeniami metodą Monte Carlo. 
Wnioski: Pomiary aktywności źródeł P-32 za pomocą specjalnie dostosowanej komory jonizacyjnej potwierdziły z dużą dokładnością 
wartości aktywności podane na świadectwie producenta.  Metody pomiarów aktywności i jednorodności źródeł przedstawione w ninie-
jszym opracowaniu pozwalają na zapewnienie wymaganej dokładności określania wielkości dawki i zapewnienie odpowiedniej jakości 
planowania leczenia w brachyterapii śródnaczyniowej.
Słowa kluczowe: brachyterapia, choroba wieńcowa, restenoza, dozymetria.
Dozymetria źródeł beta stosowanych w brachyterapii wewnątrzna-
czyniowej
Summary
Introduction: Over a period of the last ten years the application of ionizing radiation in the prevention of restenosis in cardiovascular dis-
eases has become a treatment of choice. The aim of this study was the verification of procedures used for the determination of the activi-
ty and uniformity of a P-32 wire source used in brachytherapy of cardiovascular disease.
Materials and methods: Measurements of activity and uniformity were carried out for beta P-32 radioactive sources used in the Galileo 
afterloading system from Guidant.  Measurements of activity were carried out with an ionization well chamber. Source homogeneity was 
measured with radiochromic films.
Results and discussion: The activity of the source determined on the basis of measurements with a well chamber agreed within 1.5% 
with the activity values provided by the manufacturer for each source. The results show that the activity distribution along the source length 
is homogeneous within ±5%. The dose rate fall-off as a function of the distance from the source axis measured with a radiochromic film is 
in good agreement with Monte Carlo calculations.
Conclusions: Measurements of the activity of P-32 sources with a dedicated well chamber confirm with high accuracy the results of ac-
tivity measurements provided by the manufacturer.  The methods of measurement of source activity and uniformity presented in this paper 
assure proper quality of treatment planning in cardiovascular brachytherapy.
Key words: brachytherapy, cardiovascular disease, restenosis, dosimetry.
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Figure 1.  Well chamber sensitivity as a function of source position.
energy of the emitted electrons is 1.71 MeV. The half life of 
the isotope is 14.3 days and, therefore, the source may be 
used clinically for about 4 weeks. The activity of the source, 
when delivered by the manufacturer, is about 150-160 mCi. 
The lowest acceptable activity level for treatment is about 
20 mCi, but then application times become very long.  In 
many cases, an extended application time may lead to 
acute pain to the patient caused by a decreased blood 
flow within the vessel, seriously reduced by a centering 
balloon, which is supposed to stabilize the position of the 
source in relation to the vessel wall.
 Measurements of activity were carried out with an 
ionization well chamber Standard Imaging HDR 1000+ 
Well Ionization Chamber S/N A002523, coupled with 
Victoreen 530 electrometer.  The voltage applied to the 
chamber was 300 V. The chamber had a valid calibration 
certificate from the US National Institute of Standards and 
Technology (NIST).
 The well chamber makes it possible to perform 
measurements in 4� geometry (term commonly used in 
the literature describing detectors which record quasi-
total amount of radiation emitted by a source), with a very 
high degree of reproducibility. The source is introduced to 
the well chamber through a plastic catheter of the same 
diameter as the catheter used for real clinical applications, 
which has an adapter to link it with the chamber. The 
measurements are performed as follows: the source 
is introduced to the distal position in the chamber and 
then is retracted in 2 mm steps, which gives 25 reading 
positions. In this way, the reference point of the chamber 
(the point of highest sensitivity, the so called “sweet spot”) 
is determined. In Figure 1, the chamber sensitivity is plotted 
versus source position. 
 Measurements of source homogeneity were performed 
using radiochromic films type GAF MD55 from Nuclear 
Associates [12]. The films were read using an ArtixScan 
scanner linked to a computer system with dedicated 
software for a thorough analysis of the optical density of 
the irradiated film. These measurements also allow for the 
determination of the dose rate of the source as a function 
of the distance from the source axis. These results were 
Introduction
 Over a period of the last ten years the application 
of ionizing radiation in the prevention of restenosis in 
cardiovascular diseases has become a field of intensive 
investigation. It is an example of the use of radiotherapy for 
the treatment of non-oncological diseases.
 One of the most effective methods of treatment of the 
arteriosclerotic disease is Percutaneus Transluminal Coro-
nary Angioplasty (PTCA). However, in about 50% of cases, 
the process of vascular occlusion, the restenosis occurring 
in most cases during a period of 6 months after the primary 
treatment, makes the repeated PTCA necessary [1]. 
 Restenosis is a complex process, in which the 
proliferation of neointimal and smooth muscle cells leads 
to vessel occlusion [2,3]. The use of stainless steel stents 
delays restenosis, but does not stop cell proliferation. The 
idea of using ionizing radiation to prevent restenosis has 
proved to be extremely promising. In many animal studies, 
and in the first prospective controlled clinical trials, it has 
been shown that radiation doses of the order of 10-20 Gy 
may reduce the restenosis ratio from 50% to about 10% 
[4,5,6,7,8]. 
 A variety of radiation sources have been used in 
endovascular brachytherapy so far. The isotopes most 
often used are: beta emitters- P-32, Y-90, Sr-90 and a 
gamma emitter Ir-192 [9,10]. Ir-192 is most often used in 
brachytherapy of peripheral vessels. For peripheral vessels 
conventional HDR afterloaders are generally employed. 
For cardiovascular brachytherapy various irradiation 
techniques have been used: radioactive stents, balloons 
filled with radioactive liquid, radioactive wires and seeds. 
Currently, specially designed dedicated afterloading 
devices are available [11]. 
 Dosimetry of small beta sources and treatment planning 
create specific technical and physical problems. Proper 
treatment planning requires the determination of the vessel’s 
inner diameter. This is done by means of intravascular 
ultrasound examination (IVUS). Calculation of the dose 
delivered to the target volume requires determination of 
source activity and dose distribution around radioactive 
source.
 The aim of this study was to verify procedures used in the 
determination of the activity and uniformity of a P-32 wire 
source used in brachytherapy in cardiovascular disease.
Materials and methods
 Measurements of activity and uniformity were carried 
out for beta P-32 radioactive sources used in the Galileo 
afterloading system from Guidant. The sources have the 
form of thin wires 20 or 27 mm in length. The real source 
is embedded inside the tip of the leading wire of the 
afterloader. The outer diameter of this wire is 0.46 mm. The 
isotope phosphorus 32 is a pure beta emitter. The maximum 
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Figure 2. Optical density distribution on a radiochromic ﬁlm irradiated with 
a P-32 wire source, 20 mm long, positioned in three 20 mm steps.
Figure 3. The depth dose curve for a P-32 wire source.  Points- measured 
dose, solid line- the Monte-Carlo calculations.
compared with Monte-Carlo calculations using the MCNP 
code [13].
Results and discussion
 Since the beginning of 2001, the activity of about 20 
sources has been measured. For each source, three 
series of measurements were performed. The differences 
between the three series were below 1 % for each source. 
The activity of the source determined on the basis of the 
measurements with the well chamber agreed within 1.5% 
with the activity values provided by the manufacturer for 
each source. Given such a short half life, a correction factor 
has to be calculated in terms of hours rather than days. 
The manufacturer provides the data on the uncertainty 
of the measurements with the detectors, which have the 
calibration coefficients traceable to a Primary Standard 
Dosimetry Laboratory (NIST), as �5.4% (95% confidence 
level). This accuracy applies only to the measurement of 
the contained activity of the source. Measurements of the 
dose rate in the vicinity of the source are very difficult and 
much less accurate (16 %) [11]. Primary standards for 
such measurements are being prepared and tested at the 
NIST. 
the length of 40 or 60 mm, respectively. In Figure 2, the 
results of the measurements for one of the sources, 
which is 20 mm long, and for 3 source dwell positions are 
presented. 
 The results show that the activity distribution along 
the source length is homogeneous within �5%. The 
inhomogeneity at the junction of the source dwell positions 
may be even higher. This fact has to be taken into account 
in the analysis of dose distributions for real clinical 
applications. 
 The dose rate fall-off as a function of the distance from 
the source axis, measured with a radiochromic film is 
presented in Figure 3. These results are in good agreement 
with the Monte Carlo calculations presented in the same 
figure [13].
 The analysis of dose distributions and the measurement 
methodology is under further investigation. The following 
factors influencing the absorbed dose distribution in 
cardiac vessels are being examined: the shape of the 
vessel wall as determined by IVUS, the screening effect of 
the PTCA guide wire, the presence of calcified structures 
within the vessel, etc. The results of these investigations 
will be published separately.
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 Dose rate distribution along beta sources can be 
measured with radiochromic films. The measurements 
of the uniformity of the activity distribution along the P-
32 wires can be measured with specially designed ring 
shaped ionization chambers.  Such measurements are 
much simpler than those used in the film technique.
 The results of homogeneity measurements with 
radiochromic films indicate that the distribution of activity 
along the source length is not ideally uniform. 
 The Guidant P-32 source currently used is 20 mm long 
and is used for irradiations in two or three steps, covering 
Conclusions
 Measurements of the activity of P-32 sources with 
a dedicated well chamber confirm with high accuracy 
the results of activity measurements provided by the 
manufacturer.
 Homogeneity measurements carried out with 
radiochromic films indicate certain inhomogeneities for 
particular sources. They also allow for the establishment of 
a suitable distance between the consecutive source dwell 
positions, so that the vessel wall is irradiated in the most 
uniform way possible. 
 The methods of measurements of source activity and 
uniformity verification presented in this paper assure 
proper quality of treatment planning in cardiovascular 
brachytherapy.
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